# Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

Page: https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway
Text version: https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway.md
Podcast: [Oncology Today with Dr Neil Love](https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241)
Published: 2026-07-25T13:00:00+00:00
Episode link: https://oncologytoday.captivate.fm/episode/6082-asco2026-serds-pi3k-akt-mtor-bc
Audio file: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/240a27db-2e18-410b-af36-0f9357d5f6aa.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway
Duration seconds: 7096

## Resource

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00) Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35) Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23) Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06) Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.